Patents by Inventor Edward C. Spindler, JR.

Edward C. Spindler, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for controlling blood pressure and reducing dyspnea in heart failure
    Patent number: 10881645
    Abstract: Methods for controlling, maintaining, or reducing blood pressure, and/or for treating, preventing, or alleviating symptoms such as dyspnea, in a patient suffering from or susceptible to acute heart failure. The methods involve the administration of an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound such as clevidipine. The pharmaceutical composition may be administered at an initial dose, and if blood pressure is not controlled or maintained within a target blood pressure range or reduced to within a target blood pressure range, the initial dose may be titrated to achieve a blood pressure within the target blood pressure range. The patient may have a systolic blood pressure of about 120 mmHg or above.
    Type: Grant
    Filed: October 26, 2013
    Date of Patent: January 5, 2021
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Edward C. Spindler, Jr., Loretta M. Itri, Gregory Williams, Ming-yi Hu
  • Methods for Controlling Blood Pressure and Reducing Dyspnea in Heart Failure
    Publication number: 20140121247
    Abstract: Methods for controlling, maintaining, or reducing blood pressure, and/or for treating, preventing, or alleviating symptoms such as dyspnea, in a patient suffering from or susceptible to acute heart failure. The methods involve the administration of an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound such as clevidipine. The pharmaceutical composition may be administered at an initial dose, and if blood pressure is not controlled or maintained within a target blood pressure range or reduced to within a target blood pressure range, the initial dose may be titrated to achieve a blood pressure within the target blood pressure range. The patient may have a systolic blood pressure of about 120 mmHg or above.
    Type: Application
    Filed: October 26, 2013
    Publication date: May 1, 2014
    Applicant: The Medicines Company
    Inventors: Edward C. Spindler, JR., Loretta M. Itri, Gregory Williams, Ming-yi Hu